[go: up one dir, main page]

WO2008046964A3 - Novel useful inhibitors - Google Patents

Novel useful inhibitors Download PDF

Info

Publication number
WO2008046964A3
WO2008046964A3 PCT/FI2007/050557 FI2007050557W WO2008046964A3 WO 2008046964 A3 WO2008046964 A3 WO 2008046964A3 FI 2007050557 W FI2007050557 W FI 2007050557W WO 2008046964 A3 WO2008046964 A3 WO 2008046964A3
Authority
WO
WIPO (PCT)
Prior art keywords
useful inhibitors
novel useful
relates
novel
hypoxia
Prior art date
Application number
PCT/FI2007/050557
Other languages
French (fr)
Other versions
WO2008046964A2 (en
WO2008046964A8 (en
Inventor
Panu Jaakkola
Pekka Heikkinen
Original Assignee
Panu Jaakkola
Pekka Heikkinen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20065656A external-priority patent/FI20065656A0/en
Application filed by Panu Jaakkola, Pekka Heikkinen filed Critical Panu Jaakkola
Publication of WO2008046964A2 publication Critical patent/WO2008046964A2/en
Publication of WO2008046964A3 publication Critical patent/WO2008046964A3/en
Publication of WO2008046964A8 publication Critical patent/WO2008046964A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method and an assay for identifying therapeutic lead compounds useful in treating, preventing and/or alleviating disorders related to hypoxia and/or TGF-β signalling. The invention further relates to pharmaceutical compositions and methods for detecting malignant changes.
PCT/FI2007/050557 2006-10-16 2007-10-16 Novel useful inhibitors WO2008046964A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85174206P 2006-10-16 2006-10-16
FI20065656A FI20065656A0 (en) 2006-10-16 2006-10-16 New useful inhibitors
FI20065656 2006-10-16
US60/851,742 2006-10-16

Publications (3)

Publication Number Publication Date
WO2008046964A2 WO2008046964A2 (en) 2008-04-24
WO2008046964A3 true WO2008046964A3 (en) 2008-07-10
WO2008046964A8 WO2008046964A8 (en) 2009-07-30

Family

ID=39314394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2007/050557 WO2008046964A2 (en) 2006-10-16 2007-10-16 Novel useful inhibitors

Country Status (1)

Country Link
WO (1) WO2008046964A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
WO2009047532A2 (en) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Cancer susceptibility loci
US20140120116A1 (en) * 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064770A2 (en) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
US20050164295A1 (en) * 2001-06-11 2005-07-28 Hoffmann F. M. Screen for selective inhibitors or activators of smad protein function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164295A1 (en) * 2001-06-11 2005-07-28 Hoffmann F. M. Screen for selective inhibitors or activators of smad protein function
WO2004064770A2 (en) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN X. ET AL.: "PPM1A functions as a SMAD phosphatase to terminate TGFbeta signaling", CELL, vol. 125, no. 5, June 2006 (2006-06-01), pages 915 - 928 *
NAKAGAWA T. ET AL.: "Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 287, no. 4, October 2004 (2004-10-01), pages F658 - F664 *
NAKAO A. ET AL.: "Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signalling", NATURE, vol. 389, no. 9, October 1997 (1997-10-01), pages 631 - 635, XP002927453, DOI: doi:10.1038/39369 *
ZHANG H. ET AL.: "Cellular response to hypoxia involves signaling via Smad proteins", BLOOD, vol. 101, no. 6, March 2003 (2003-03-01), pages 2253 - 2260 *

Also Published As

Publication number Publication date
WO2008046964A2 (en) 2008-04-24
WO2008046964A8 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
EP1987141B8 (en) Compositions suitable for treating collagen-mediated diseases
AP2332A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
AP2007003973A0 (en) Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
IL182837A0 (en) Methods, assays and compositions for treating retinol-related diseases
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
AU2007288337A8 (en) Compounds for treating proliferative disorders
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2008038127A8 (en) Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
EP2101567A4 (en) COMPOSITIONS AND METHODS FOR DETECTING, TREATING OR PREVENTING REDUCING STRESS
WO2008013660A3 (en) Inhibitors of advanced glycation end products
WO2007101063A3 (en) Treatment of development-related disorders
WO2007050673A3 (en) Cyclin dependent kinase inhibitors
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2008046964A8 (en) Novel useful inhibitors
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
WO2007116029A3 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
ZA200703661B (en) Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
WO2008135639A3 (en) Novel useful inhibitors
WO2006091962A3 (en) Detection of compounds that affect therapeutic activity
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823194

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07823194

Country of ref document: EP

Kind code of ref document: A2